

## Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9

April 28, 2022

CONSHOHOCKEN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), will report its first quarter 2022 financial results on Monday, May 9, 2022 and provide business and clinical program updates with some additional results from the Phase 3 MAESTRO-NAFLD-1 study.

The schedule for the press release and conference call/webcast is as follows:

Press Release:	May 9 <sup>th</sup> , 2022 at 6:30 am ET
Conference Call:	May 9 <sup>th</sup> , 2022 at 8:00 am ET
Domestic Dial-In Number:	(833) 660-2754
International Dial-In Number:	(409) 350-3497
Conference ID Number:	9765409

To access the live webcast of the call please visit the Investor Events and Presentations section of Madrigal's <u>website</u> or click <u>here</u>. An archived webcast will be available on the Madrigal website after the event.

## **About Madrigal Pharmaceuticals**

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.

## **Investor Contact**

Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

## Media Contact

Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com



Source: Madrigal Pharmaceuticals, Inc.